To define the cell populations that drive joint inflammation in rheumatoid arthritis (RA), we applied single-cell RNA sequencing (scRNA-seq), mass cytometry, bulk RNA-seq and flow cytometry to T cells, B cells, monocytes and fibroblasts from 51 samples of synovial tissue from patients with RA or osteoarthritis. Utilizing an integrated strategy based on canonical correlation analysis of 5,265 scRNA-seq profiles, we identified 18 unique cell populations. Combining mass cytometry and transcriptomics together revealed cell states expanded in RA synovia:
THY1(CD90)
+
HLA-DRA
hi
sublining fibroblasts,
IL1B
+
pro-inflammatory monocytes,
ITGAX
+
TBX21
+
autoimmune-associated B cells and
PDCD1
+
T peripheral helper (Tph) and T follicular helper (Tfh). We defined distinct subsets of CD8
+
T cells characterized by a
GZMK
+
,
GZMB
+
and
GNLY
+
phenotype. We mapped inflammatory mediators to their source cell populations; for example, we attributed
IL6
expression to
THY1
+
HLA-DRA
hi
fibroblasts, and
IL1B
production to pro-inflammatory monocytes. These populations are potentially key mediators of RA pathogenesis.
Wei, Slowikowski, Fonseka, Rao et al A single cell map of the RA joint Abstract 78 To define the cell populations in rheumatoid arthritis (RA) driving joint inflammation, we applied 79 single-cell RNA-seq (scRNA-seq), mass cytometry, bulk RNA-seq, and flow cytometry to sorted 80 T cells, B cells, monocytes, and fibroblasts from 51 synovial tissue RA and osteoarthritis (OA) 81 patient samples. Utilizing an integrated computational strategy based on canonical correlation 82 analysis to 5,452 scRNA-seq profiles, we identified 18 unique cell populations. Combining mass 83 cytometry and transcriptomics together revealed cell states expanded in RA synovia: 84 THY1 + HLA high sublining fibroblasts (OR=33.8), IL1B + pro-inflammatory monocytes (OR=7.8), 85 CD11c + T-bet + autoimmune-associated B cells (OR=5.7), and PD-1 + Tph/Tfh (OR=3.0). We also 86 defined CD8 + T cell subsets characterized by GZMK + , GZMB + , and GNLY + expression. Using 87 bulk and single-cell data, we mapped inflammatory mediators to source cell populations, for 88 example attributing IL6 production to THY1 + HLA high fibroblasts and naïve B cells, and IL1B to 89 pro-inflammatory monocytes. These populations are potentially key mediators of RA 90 pathogenesis. 91 92 93 94 95 96 97 98 99 100
ObjectiveTo establish in a global setting the relationships between countries’ socioeconomic status (SES), measured biological disease modifying antirheumatic drug (bDMARD)-usage and disease outcomes. To assess if prescription and reimbursement rules and generic access to medication relates to a countries’ bDMARD-usage.MethodsData on disease activity and drug use from countries that had contributed at least 100 patients were extracted from the METEOR database. Mean disease outcomes of all available patients at the final visit were calculated on a per-country basis. A questionnaire was sent to at least two rheumatologists per country inquiring about DMARD-prices, access to treatment and valid regulations for prescription and reimbursement.ResultsData from 20 379 patients living in 12 different countries showed that countries’ SES was positively associated with measured disease activity (meanDAS28), but not always with physical functioning (HAQ-score). A lower country’s SES, stricter rules for prescription and reimbursement of bDMARDs as well as worse affordability of bDMARDs were associated with lower bDMARD-usage. bDMARD-usage was negatively associated with disease activity (although not with physical functioning), but the association was moderate at best.ConclusionsDisease activity in patients with rheumatoid arthritis as well as bDMARD-usage varies across countries worldwide. The (negative) relationship between countries’ bDMARD-usage and level of disease activity is complex and under the influence of many factors, including—but not limited to—countries’ SES, affordability of bDMARDs and valid prescription and reimbursement rules for bDMARDs.
ObjectivesTo compare consecutive disease modifying antirheumatic drug (DMARD)-treatment regimes in daily practice in patients with rheumatoid arthritis (RA) who failed on initial methotrexate, while using a multiple propensity score (PS) method to control for the spurious effects of confounding by indication.MethodsPatients with newly diagnosed RA who had failed initial treatment with methotrexate were selected from METEOR, an international, observational registry. Subsequent DMARD-treatment regimens were categorised as: (1) conventional synthetic DMARD(s) (csDMARD(s)) only (143 patients), (2) csDMARD(s)+glucocorticoid (278 patients) and (3) biological DMARD (bDMARD)±csDMARD(s) (89 patients). Multiple PS that reflect the likelihood of treatment with each treatment-regime were estimated per patient using multinomial regression. Linear mixed model analyses were performed to analyse treatment responses per category (Disease Activity Score (DAS)) after a maximum follow-up duration of 6 and 12 months, and results were presented with adjustment for the multiple PS.ResultsAfter 6 months, follow-up PS-adjusted treatment responses yielded a change in DAS per year (95% CI) of −2.00 (−2.65 to −1.36) if patients received a bDMARD; of −0.96 (−1.33 to −0.59) if patients received csDMARD(s)+glucocorticoids and of −0.73 (−1.21 to −0.25) if patients received csDMARDs only. These changes were −0.91 (−1.23 to −0.60); −0.43 (−0.62 to −0.23) and −0.39 (−0.66 to −0.13), respectively after 1 year of follow-up.ConclusionsIn this analysis of worldwide common practice data with adjustment for multiple PS, patients with RA who had failed initial treatment with methotrexate monotherapy had a better DAS-response after a subsequent switch to a bDMARD-containing treatment regimen than to a regimen with csDMARD(s) only, with or without glucocorticoids.
BackgroundTumor necrosis factor alpha (TNFα) is a key cytokine in both the pathogenesis of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) and the host defense against tuberculosis (TB). Consequently, anti-TNFα medications result in an increased risk of latent TB infection (LTBI) reactivation. Here, we sought to evaluate the factors affecting the results of QuantiFERON-TB Gold In-Tube (QFT-GIT) assay as a screening tool for LTBI.MethodsWe conducted an observational, retrospective study in patients with IBD and RA who underwent LTBI screening using QFT-GIT at UMass Memorial Medical Center between 2008 and 2016 prior to initiation of anti-TNF medications.ResultsWe included 107 and 89 patients with IBD and RA, respectively. We found that a higher proportion of IBD patients had indeterminate QFT-GIT result compared to RA patients. Furthermore, we found that the majority of patients with indeterminate results were tested during an acute flare of IBD (88%) and while taking corticosteroids. Of all patients receiving ≥20 mg equivalent prednisone dose (n=32), 63% resulted in indeterminate QFT-GIT, compared to only 6% indeterminate testing in patients receiving <20 mg of equivalent prednisone dose (n=164, P<0.001). There was no correlation between indeterminate results and age, gender, disease duration, or distribution, or smoking status within each population.ConclusionWe observed that high-dose corticosteroids may affect QFT-GIT outcomes leading to a high proportion of indeterminate results. We propose that IBD patients should be tested prior to initiation of corticosteroids to avoid equivocal results and prevent potential delays in initiation of anti-TNF medications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.